Journal Article

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial

  • Bekaii-Saab T
  • Melisi D
  • Wilmink H
  • et al.
Journal of Clinical Oncology (2026)
DOI: 10.1200/jco-26-00788
1Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Bekaii-Saab, T. S., Melisi, D., Wilmink, H., Garufi, C., Tran, N., Tortora, G., … Vogel, A. (2026). Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-00788

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free